The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 06, 2018

Filed:

Jun. 27, 2008
Applicants:

Mark L. Lupher, Jr., Chester Springs, PA (US);

Teresa K. Surowy, Kenosha, WI (US);

Shawn LI, Exton, PA (US);

David Paul Hesson, Malvern, PA (US);

Michael Scott Kramer, Harleysville, PA (US);

Inventors:

Mark L. Lupher, Jr., Chester Springs, PA (US);

Teresa K. Surowy, Kenosha, WI (US);

Shawn Li, Exton, PA (US);

David Paul Hesson, Malvern, PA (US);

Michael Scott Kramer, Harleysville, PA (US);

Assignee:

Promedior, Inc., Lexington, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 14/47 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4737 (2013.01); G01N 33/6887 (2013.01); G01N 2333/4709 (2013.01); G01N 2333/4737 (2013.01); G01N 2800/085 (2013.01); G01N 2800/382 (2013.01);
Abstract

The application provides methods for determining a patient's risk for developing fibrosis or a fibrosis-related disorder. Concentrations of C reactive protein (CRP) and serum amyloid protein (SAP) are measured from a biological sample to determine the SAP-to-CRP ratio. This ratio can then be compared with one or more SAP-to-CRP reference ratios to determine a patient's risk for developing a fibrosis related disorder. The diagnostic methods can also be used to determine the severity of fibrosis in a patient afflicted with such a disease. Furthermore, methods for treating patients having a fibrosis-related disorder are provided. For example, a patient that has a lower SAP-to-CRP ratio than one or more reference values may be treated with an SAP agonist and/or CRP antagonist to treat or prevent a fibrosis disorder. The methods may further comprise determining the R131/H131 polymorphism of FcγRIIA as a risk factor for developing fibrosis or a fibrosis-related disorder.


Find Patent Forward Citations

Loading…